Recursion Pharmaceuticals, Inc. (RXRX) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
RXRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
RXRX Revenue Analysis (2019–2025)
As of February 28, 2026, Recursion Pharmaceuticals, Inc. (RXRX) generated trailing twelve-month (TTM) revenue of $74.6 million, reflecting explosive growth of +687.8% year-over-year. The most recent quarter (Q4 2025) recorded $35.5 million in revenue, up 586.7% sequentially.
Looking at the longer-term picture, RXRX's 5-year compound annual growth rate (CAGR) stands at +85.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $74.7 million in 2025, representing a new all-time high.
Revenue diversification analysis shows RXRX's business is primarily driven by License and Service (99%), and Grant (1%). With over half of revenue concentrated in License and Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY), RXRX has outperformed the peer group in terms of revenue growth. Compare RXRX vs REGN →
Peer Comparison
Compare RXRX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RXRXCurrent | $75M | +687.8% | +85.4% | -867.9% | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% | |
| ROIV | $29M | -56.4% | -15.6% | -3453.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $74.7M | +26.9% | $3.7M | 5.0% | $-648,132,000 | -867.9% |
| 2024 | $58.8M | +34.1% | $13.6M | 23.1% | $-479,004,000 | -814.1% |
| 2023 | $43.9M | +10.6% | $1.3M | 2.9% | $-350,060,000 | -797.8% |
| 2022 | $39.7M | +296.8% | $-8,594,000 | -21.7% | $-245,727,000 | -619.3% |
| 2021 | $10.0M | +193.0% | $10.0M | 100.0% | $-182,775,000 | -1827.8% |
| 2020 | $3.4M | +99.5% | $3.4M | 100.0% | $-84,615,000 | -2479.2% |
| 2019 | $1.7M | - | $-44,098,000 | -2577.3% | $-62,441,000 | -3649.4% |
See RXRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RXRX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RXRX vs AGIO
See how RXRX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RXRX's revenue growth accelerating or slowing?
RXRX revenue is accelerating at +687.8% year-over-year, exceeding the 5-year CAGR of +85.4%. TTM revenue reached $75M. Growth momentum has increased versus prior periods.
What is RXRX's long-term revenue growth rate?
Recursion Pharmaceuticals, Inc.'s 5-year revenue CAGR of +85.4% reflects the sustained expansion pattern. Current YoY growth of +687.8% is above this long-term average.
How is RXRX's revenue distributed by segment?
RXRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.